Airsupra (albuterol and budesonide) inhalation aerosol
Recall D-0444-2025, part of FDA recall event 96857. See AsttraZeneca Pharmaceuticals's company page.
AsttraZeneca Pharmaceuticals LP started this Class II drug recall on May 14, 2025 (voluntary: firm initiated); FDA lists it as ongoing.
- Classification: Class II
- Started: May 14, 2025
- Status: Ongoing
Defective delivery system
- Product
- Airsupra (albuterol and budesonide) inhalation aerosol, 90 mcg/80 mcg per inhalation, packaged in a) 120-inhalation canister (NDC 0310-9080-12) b) 28-inhalation canister (NDC 0310-9080-28), Rx only, Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, By: AstraZeneca Dunkerque Production (AZDP), Dunkerque, France, Product of France, .
- Quantity
- a) 807,837 canisters; b) 235,698 canisters
- Lots and codes
- Lot#: a) 6270044C00, 6270040D00, 6270034E00, Exp Date 10/2026; 6270053C00, 6270045C00, 6270047C00, 6270056C00, 6270052C00, 6270063E00 Exp 11/30/2026; 6270064C00, 6270071D00, 6270075D00, 6270075F00 Exp Date 12/31/2026; 6270107C00, Exp Date 9/30/2027; b) Lot 6270019E00, Exp Date 7/31/2025; 6270021D00, Exp 8/31/2025; 6270095C00, Exp 2/28/2026
- Distribution
- USA Nationwide
- Recalling firm
- AsttraZeneca Pharmaceuticals LP, Wilmington, DE, United States
- How the firm notified
- Letter
- FDA classified
- May 21, 2025
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports